- Previous Close
0.00 - Open
24.57 - Bid 28.02 x 40000
- Ask 34.20 x 40000
- Day's Range
24.57 - 24.57 - 52 Week Range
24.57 - 24.57 - Volume
140 - Avg. Volume
0 - Market Cap (intraday)
699.486M - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
25.86 - EPS (TTM)
0.95 - Earnings Date Apr 24, 2025 - Apr 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.
www.torii.co.jp583
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: TRXPF
View MorePerformance Overview: TRXPF
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRXPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRXPF
View MoreValuation Measures
Market Cap
827.71M
Enterprise Value
537.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
9.18%
Return on Assets (ttm)
3.13%
Return on Equity (ttm)
4.39%
Revenue (ttm)
57.25B
Net Income Avi to Common (ttm)
5.25B
Diluted EPS (ttm)
0.95
Balance Sheet and Cash Flow
Total Cash (mrq)
42.17B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
204.88M